Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.39 |
| ▸ | MC4R | P32245 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3487314 | 0.88 | CCR1 (0.44) | CCR1CHRM2CHRM1CHRM3POLB | |
| SCHEMBL4909423 | 0.83 | CCR1 (0.50) | CCR1CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL3488494 | 0.79 | DRD2 (0.52) | DRD2 | |
| SCHEMBL15130431 | 0.77 | CHRM5 (0.48) | CCR1CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL15191011 | 0.77 | CHRM5 (0.48) | CCR1CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL5555057 | 0.76 | CCR1 (0.60) | CCR1CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL4119272 | 0.76 | CHRM5 (0.52) | CCR1CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL4119281 | 0.76 | CHRM5 (0.52) | CCR1CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL15191066 | 0.75 | CCR1 (0.39) | CCR1MC4RCHRM2CHRM1CHRM3 | |
| SCHEMBL15191067 | 0.75 | CCR1 (0.39) | CCR1MC4RCHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100075973-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-25 | — | — | US | disclosed |
| WO-2010025073-A1 | DIHYDROIMIDAZO [ 1, 5-F] PTERIDINES AS POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075973-A1 | POLO-LIKE KINASE INHIBITORS | PLK2, PLK4, PLK1 | CCR1 4556/4885MC4R 4537/4885CHRM2 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.